DepYmed Receives FDA Orphan Drug Designation for Clinical Candidate DPM-1001 for the Treatment of Wilson Disease FARMINGDALE, N.Y., May 23, 2022 (GLOBE NEWSWIRE) -- DepYmed Inc. (“DepYmed” or the “Company”) is a preclinical stage pharmaceutical company focused on developing transformative treatments for rare...

DepYmed Receives FDA Rare Pediatric Disease and Orphan Drug Designations for Its Lead Clinical Candidate for the Treatment of Rett Syndrome FARMINGDALE, N.Y., May 03, 2022 (GLOBE NEWSWIRE) -- DepYmed Inc. (“DepYmed” or the “Company”) is a preclinical stage pharmaceutical company focused on developing transformative treatments for rare...

DepYmed and Monash Biomedicine Discovery Institute to Study the Role of a New Generation of PTP1B Inhibitors against a Novel Intracellular Checkpoint in Cancer Research Agreement Capitalizes on Newly Published Monash Findings in Peer Reviewed Journal Cancer Discovery1 that PTP1B acts as an Intracellular Checkpoint and PTP1B Inhibition Represses Tumor Growth ...